Risk score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients
A partir de 58 échantillons tumoraux prélevés sur des patients atteints d'un glioblastome multiforme, cette étude identifie une signature, basée sur l'expression de 6 micro-ARNs, en association avec la survie sans progression et la survie globale des patients
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. The prognosis of GBM patients varies considerably and the histopathological examination is not sufficient for individual risk estimation. MicroRNAs (miRNAs) are small, non-coding RNAs that function as posttranscriptional regulators of gene expression and were repeatedly proved to play important roles in pathogenesis of GBM. In our study, we performed global miRNA expression profiling of 58 glioblastoma tissue samples obtained during surgical resections and 10 non-tumor brain tissues. The subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples. Correlation with clinical data led to identification of 6-miRNA signature significantly associated with progression free survival (HR 1.98, CI 95% [1.33-2.94], p<0.001) and overall survival (HR 2.86, CI 95% [1.91-4.29], p<0.001). MGMT methylation status was evaluated as reference method and risk score based on 6-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients. Multivariate Cox analysis indicated that the risk score based on 6-miRNA signature is an independent prognostic classifier of GBM patients. We suggest that the risk score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients.
Carcinogenesis , résumé, 2014